



Original Article

## Comparison between the triamcinolone and bevacizumab subconjunctivals and changes in Interleukin-1 mRNA expression in pterygium

Purnamanita Syawal, PhD<sup>a</sup>, Budu Budu, PhD<sup>b</sup>, Mochammad Hatta, PhD<sup>c,\*</sup>,  
Muhammad Nasrum Massi, PhD<sup>c</sup>, Andi Muhammad Ichsan, PhD<sup>b</sup> and  
Rahmawati Minhajat, PhD<sup>d</sup>

<sup>a</sup> Department of Ophthalmology, Public Eye Centre Makassar, Indonesia

<sup>b</sup> Department of Ophthalmology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

<sup>c</sup> Department of Molecular Biology and Immunology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

<sup>d</sup> Division of Haematology Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Received 3 May 2021; revised 8 July 2021; accepted 22 July 2021; Available online 16 August 2021



### المخلص

**أهداف البحث:** الظفرة هي كتلة العين الخارجية الليفية الوعائية التي تنمو من ملتحمه إلى القرنية. لم يتم التحقيق في تأثير الحقن تحت الملتحمه لتريامسينولون وبيفاسيزوماب بشكل كاف في جميع أنحاء العالم. تهدف هذه الدراسة إلى تحليل تعبير انترلوكين-1 بعد حقن تريامسينولون وبيفاسيزوماب تحت الملتحمه.

**طرق البحث:** تم تقسيم جميع المرضى بصورة عشوائية إلى ثلاث مجموعات. كل 5 عيون في مجموعة تريامسينولون ومجموعة بيفاسيزوماب ومجموعة الدواء الوهمي. تم حقن جميع الأشخاص تحت الملتحمه قبل أسبوع واحد من الجراحة، ثم أجريت الجراحة بتقنية الطعم الذاتي. تضمنت مقاييس النتائج الرئيسية تغييرات في تعبير انترلوكين-1 حمض ريبونوكليك المرسل بين مجموعة تريامسينولون، بيفاسيزوماب، ومجموعات الدواء الوهمي.

**النتائج:** تم الانتهاء من جميع العينات بعد شهر واحد من المتابعة. كانت التغييرات في مستويات الدم لتعبير انترلوكين-1 حمض ريبونوكليك المرسل في مجموعة بيفاسيزوماب  $0.52 \pm 4.81$ ، وكانت مجموعة تريامسينولون  $2.63 \pm 3.40$ ، وكانت مجموعة الدواء الوهمي  $1.08 \pm 1.48$ ، على التوالي. في المقارنة بين المجموعات، كان هناك تأثير معنوي بين مجموعة بيفاسيزوماب ومجموعة

الدواء الوهمي،  $3.73 \pm 1.12$ ، مع عدم وجود تأثير معنوي في مجموعة تريامسينولون،  $1.40 \pm 1.12$ .

**الاستنتاجات:** كان الحقن تحت الملتحمه بيفاسيزوماب وتريامسينولون قبل الجراحة فعالاً في قمع الالتهاب في الظفرة.

**الكلمات المفتاحية:** بيفاسيزوماب؛ انترلوكين-1 حمض ريبونوكليك المرسل؛ الظفرة؛ الحقن تحت الملتحمه تريامسينولون.

### Abstract

**Objectives:** Pterygium is a fibrovascular external ocular mass that grows from the conjunctiva into the cornea. The effect of subconjunctival injection of triamcinolone and bevacizumab has been inadequately investigated worldwide. This study aims to analyse the expression of IL-1 after the injection of triamcinolone and bevacizumab subconjunctiva.

**Methods:** All patients are randomized into three groups: the triamcinolone, bevacizumab group, and placebo groups, with 5 patients in each in group. All subjects are injected subconjunctivally one week before surgery, and then surgery is performed with the autograft technique. The main outcome measures include changes in the IL-1 mRNA expression between the triamcinolone, bevacizumab, and placebo groups.

**Results:** All samples are completed after one month of follow-up. The changes in blood levels of mRNA IL-1

\* Corresponding address: Molecular Biology and Immunology Laboratory, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.

E-mail: [hattaram@yahoo.com](mailto:hattaram@yahoo.com) (M. Hatta)

Peer review under responsibility of Taibah University.



expression are as follows:  $4.81 \pm 0.52$  in the bevacizumab group,  $3.40 \pm 2.63$  in the triamcinolone group, and  $1.08 \pm 1.48$  in the placebo group ( $p = 0.04$ ). In the comparison between groups, there is a significant effect between the bevacizumab and placebo groups,  $3.73 \pm 1.12$  ( $p = 0.00$ ), with no significant effect in the triamcinolone group,  $1.40 \pm 1.12$  ( $p = 0.06$ ).

**Conclusion:** The subconjunctival injection of bevacizumab and triamcinolone before surgery is effective in suppressing inflammation in pterygium.

**Keywords:** Bevacizumab; mRNA IL-1; Pterygium; Subconjunctival injection; Triamcinolone

© 2021 The Authors.

Production and hosting by Elsevier Ltd on behalf of Taibah University. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

## Introduction

Pterygium is a fibrovascular conjunctiva that grows from the limbus to the corneal surface.<sup>1</sup> Although the exact cause remains unclear, there is a relationship between prolonged exposure to UV light and the pterygium mechanism. Studies on molecular mechanisms, such as proliferation cell factors, inflammatory mediators and growth factors, matrix metalloproteinases, and angiogenesis, have identified factors related to the pathomechanisms of pterygium.<sup>2–5</sup> Epidemiological studies have shown that ultraviolet B (UV B) is the major risk factor for pterygium recurrence<sup>5,6</sup> and triggers inflammation and progressive fibrovascular proliferation on the ocular surface after long-term exposure.<sup>5</sup> The recurrence rate post excision of pterygium cases was still high (30%–90%), and 97% occurred within one-year period post-excision.<sup>7</sup> Chronic UV light creates limbal basal stem cell barrier dysfunction resulting in conjunctival epithelial cell spreading to the cornea and a subsequent upregulation of proinflammatory cytokine such as Interleukin 1.<sup>8</sup> The inflammation process in the conjunctiva is one of the factors involved in the recurrence process associated with pterygium. The role of corticosteroids in preventing recurrence of pterygium is well known. Triamcinolone is a medium-potency steroid that plays an important role in inflammation by decreasing fibroblast activity<sup>9</sup> and inhibiting angiogenesis by vascular endothelial cells and other cells in pterygium tissues.<sup>10</sup> Intraoperative subconjunctival triamcinolone injection has been shown to be effective in inhibiting the recurrence of pterygium.<sup>11</sup> Another factor involved in the progression of pterygium is increasing growth factor vascular endothelial growth factor (VEGF).<sup>12</sup> Bevacizumab is a humanized monoclonal antibody that inhibits VEGF-A, which stimulates angiogenesis.<sup>11,13</sup> Intralesional administration has been proven to decrease pterygium size up to 14.47%.<sup>13</sup> In 2017, Gupta et al.<sup>11</sup> revealed that subconjunctival administration

of 2.5 mg of bevacizumab was effective in preventing the recurrence of pterygium. This study aims to analyse changes in the expression of messenger RNA (mRNA) interleukin-1 (IL-1) after injection of 20 mg of triamcinolone and 2.5 mg of bevacizumab subconjunctiva in pterygium patients.

## Materials and Methods

### *Study design and subjects*

We consecutively enrolled 15 adult patients (30–45 years old) who had a clinically confirmed diagnosis of stage II primary pterygium according to the Bhargava et al. classification.<sup>14</sup> The 15 eye patients underwent a series of examinations, such as visual acuity and slit lamp examination, to determine the type and stage of pterygium, intraocular pressure, blood pressure, and random blood sugar before injection. Exclusion criteria were infection or any ocular surface disease, systemic disease (such as diabetes mellitus, hypertension, autoimmune disorders), and previous ocular/pterygium surgery. Patients were randomized into three groups (bevacizumab, triamcinolone, and placebo groups) consisting of 5 patients for each group. Each eye received a subconjunctival injection of 2.5 mg of bevacizumab, 20 mg of triamcinolone, or a placebo (depending on the group) seven days prior to pterygium excision.

### *Surgical procedures*

All 15 eye pterygium patients underwent surgery by a single surgeon (P) with the autograft conjunctival technique. First, after anaesthesia with lidocaine was administered, there was a 2% injection into the subconjunctiva, followed by an injection in the pterygium area, which was approximately 5 mm from the corneal limbus. After that, we started to excise and remove the pterygium tissue from the apex to the body, leaving a triangular-shaped bare sclera. Then a conjunctival graft was made, with excision of the autolimbal conjunctiva from the superior bulbar conjunctiva. Next, a graft was used to cover the pterygium excision and was sutured using Vicryl 8–0. Post-operatively, antibiotics and steroid eye drops (Cendo Xitrol<sup>®</sup>) were administered four times daily. Evaluation was performed on the first day, after seven days, and four weeks after surgery to assess signs of inflammation and recurrence post-operatively.

### *Sample collection and measurement of interleukin-1 mRNA expression*

Blood samples were collected one week prior to surgery and one month after surgery. The samples were stored at  $-20\text{ }^{\circ}\text{C}$  until assayed.

The mRNA expression of IL-1 was measured using real-time PCR according to the methods of previous studies.<sup>15–17</sup>

*Statistical analysis*

All data are presented in the table and expressed as the mean ± standard deviation (SD). Statistical analyses were performed using Statistical Package for Social Science (SPSS) version 21.0. Changes in the mRNA expression of IL-1 using the chi square and Kruskal–Wallis tests were used. The differences between groups were tested using one-way ANOVA with a post hoc Least Significant Difference (LSD) test. A value of  $p < 0.05$  was considered a statistically significant result.

**Results**

Fifteen patients receiving the aforementioned eye treatment received follow-ups for a period of one month. The Kruskal–Wallis test for the changes in IL-1 mRNA was significant at  $p = 0.036$ . Changes in IL-1 mRNA expression with the Kruskal–Wallis test were significant at  $p = 0.036$ . The highest changes in IL-1 mRNA levels were found in the bevacizumab group. There were significant effects on blood level changes in mRNA IL-1 expression in the three groups: in the bevacizumab group, it was  $4.81 \pm 0.52$ ; in the triamcinolone group, it was  $3.40 \pm 2.63$ ; and in the placebo group, it was  $1.08 \pm 1.48$  ( $p = 0.04$ ) (Table 1).

In the comparison between groups, there was no significant effect in the triamcinolone group,  $1.40 \pm 1.12$  ( $p = 0.06$ ), whereas in the bevacizumab group and placebo group, there was a significant effect,  $3.73 \pm 1.12$  ( $p = 0.00$ ) (Table 2).

**Discussion**

In this study, we found, as shown in Table 1, that the level of IL-1 mRNA in the bevacizumab group was higher than those of the triamcinolone and placebo groups, and there were significant changes in IL-1 mRNA expression in the bevacizumab group. In 2008, Bahar et al.<sup>18</sup> used the same dose of bevacizumab as in our study and found that it did not result in long-term vascular regression in the cornea for recurrent pterygium. In 2010, Razeghinejad<sup>19</sup> reported that intraoperative subconjunctival bevacizumab was not effective in pterygium recurrence. These results support our results because IL-1 is a proinflammatory cytokine that plays a role in inflammation, which is a major factor in post-operative pterygium recurrence.

Our study administered triamcinolone before surgery, whereas Kheirkhah et al. (2013<sup>20</sup>) administered an intraoperative triamcinolone injection and showed that it did not significantly reduce conjunctival inflammation. This result could also support our study results that triamcinolone treatment did not reduce the mRNA expression of IL-1, which led to inflammation and pterygium recurrence. Our results were also contrary to those of other studies about bevacizumab and triamcinolone. Castañeda (2015<sup>21</sup>) reported that a triple subconjunctival injection of 2.5 mg/0.1 mL of bevacizumab (first day, 15 days, and four weeks after the first injection), and surgery using a conjunctival autograft procedure can prevent pterygium recurrence. In our study, only one injection of bevacizumab was administered one week before surgery. Nuzzi (2017<sup>22</sup>) showed that bevacizumab injection

**Table 1: Level changes in IL-1 mRNA expression after subconjunctival injection of each agent.**

Group	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Minimum	Maximum
					Lower Bound	Upper Bound		
Bevacizumab	5	4.81	0.52	0.23	4.16	5.45	4.35	5.63
Triamcinolone	5	3.40	2.63	1.17	0.14	6.67	0.17	5.84
Placebo	5	1.08	1.48	0.66	-0.76	2.92	0.00	3.04
Total	15	3.10	2.28	0.59	1.83	4.36	0.00	5.84

**Table 2: Comparison of mRNA IL-1 blood level changes between groups.**

(I) Group	(J) Group	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
Bevacizumab	Triamcinolone	1.40	1.12	0.23	-1.03	3.83
	Placebo	3.73*	1.12	0.00	1.30	6.16
Triamcinolone	Bevacizumab	-1.40	1.12	0.23	-3.94	1.03
	Placebo	2.33	1.12	0.06	-0.11	4.77
Placebo	Bevacizumab	3.73*	1.12	0.00	-6.16	-1.30
	Triamcinolone	-2.33	1.12	0.06	-4.77	0.11

\*The mean difference is significant at the 0.05 level.

subconjunctivally one week prior to surgery had a lower recurrence rate than the control. Although this result seems to contradict our result, in their study, they also reported a 7.14% recurrence after bevacizumab injection. This means that the inflammation process could still occur after bevacizumab injection and accordingly with IL-1 as a cytokine. Gupta RK (2017)<sup>11</sup> revealed that using triamcinolone and bevacizumab as adjuncts can result in undesirable side effects. Mpyet (2000)<sup>23</sup> also found that combined subconjunctival and mitomycin C intraoperatively was effective in preventing recurrence up to 14 months based on follow-up. Our different results from other studies possibly occurred because we could test changes in mRNA IL-1 expression in blood but not in conjunctival tissue because we did not have a baseline for pterygium tissues. Many factors could influence the systemic condition, and this was subject to biases.

In the comparison between groups, as shown in Table 2, there were significant differences between the bevacizumab and placebo groups ( $p < 0.05$ ). Bevacizumab can inhibit VEGF as well as the proliferation of fibrovascular tissue. VEGF is a key factor in remodelling wound healing tissue.<sup>24</sup> IL-1 is a proinflammatory mediator that influences the inflammatory process and promotes immune and growth responses. The growth of a new capillary as a response to angiogenesis plays an important role as a response to injury, such as in wound healing. These processes can be suppressed by a vascular growth factor.<sup>25–28</sup> In our study, we used a triamcinolone subconjunctival that can inhibit inflammation and bevacizumab, which inhibits angiogenesis, and found that the mRNA expression of IL-1 in the bevacizumab group was higher than that in the triamcinolone group. Therefore, bevacizumab seemed more effective than triamcinolone in preventing recurrence after excision. Accordingly, pre-surgery injection of 20 mg of triamcinolone and 2.5 mg of bevacizumab into the subconjunctiva was effective in suppressing inflammation in pterygium patients. Kang et al.<sup>29</sup> found that the inhibitory effect of anti-VEGF in the treatment of corneal neovascularization was not significant, although triamcinolone and bevacizumab were combined.

The results reported here have some limitations. The weakness of this study was that only 15 subject eyes were studied. The participants were observed until only one month after surgery. Because pterygium recurrence was highly locally related, our results could not support the effect of both triamcinolone and bevacizumab in reducing the recurrence risk of pterygium after excision because we only observed recurrence for one month after surgery. We were unable compare pterygium tissue before surgery due to ethical factors, so we cannot compare it as we did in the blood sample, before and after giving an injection.

Therefore, this study requires further research on the role of mRNA IL-1 expression and what factors are involved in it.

## Conclusion

The expression of IL-1 mRNA in the bevacizumab group was higher than that in the triamcinolone and placebo groups, so Bevacizumab seems more effective than triamcinolone in preventing recurrence after excision.

## Recommendation

Further follow-ups are needed because in this study, we only followed up with patients twice (once after seven days and then one month after surgery) and we did not observe recurrence during this period. We suggest evaluating pterygium tissue after treatment.

## Source of funding

This research did not receive any specific grant from funding agencies in the public, commercial, or non-profit sectors.

## Conflict of interest

The authors have no conflicts of interest to declare.

## Ethical approval

This study was approved by the Institutional Review of Research Board Ethics Committee of Medical Faculty of Hasanuddin University, Makassar, South Sulawesi, Indonesia, No. 416/H4.8.4.5.31/PP36-KOMETIK/2018; Date: 21 June 2018.

## Patients consent

Written informed consent for injection, surgery, blood sampling, and pterygium sampling was obtained from all participants according to the principles outlined in the Declaration of Helsinki.

## Authors' contributions

PP, BB, MH, MNM, AMI, and RM conceived and designed the study, conducted the research, provided materials, collected and organized the data, drafted the manuscript, analyzed and interpreted the data. All authors critically reviewed and approved the final draft article and are responsible for the content and similarity index of the manuscript.

## Acknowledgment

We thank all registered patients at the Public Eye Health Centre of Makassar, Indonesia who participated in the study and Romi Usman, Mus Helminus, and Marwani in the Molecular Biology and Immunology Laboratory for Infection Diseases, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.

## References

1. Carlock BH, Bienstock CA, Rogosnitzky M. Pterygium: nonsurgical treatment using topical dipyrindamole – a case report. *Case Rep Ophthalmol* 2014; 5(1): 98–103. <https://doi.org/10.1159/000362113>.
2. Wanzeler ACV, Barbosa IAF, Duarte B, Borges D, Barbosa EB, Kamiiji D, et al. Mechanisms and biomarker candidates in pterygium development. *Arq Bras Oftalmol*



- 2019; 82(6): 528–536. <https://doi.org/10.5935/0004-2749.20190103>.
3. Chui J, Giloramo ND, Wakefield D, Coroneo MT. The Pathogenesis of Pterygium: current concepts and their therapeutic implications. *Ocul Surf* 2008; 6(1): 24–43. [https://doi.org/10.1016/s1542-0124\(12\)70103-9](https://doi.org/10.1016/s1542-0124(12)70103-9).
  4. Cárdenas-Cantù E, Zavala J, Valenzuela J, Valdez-García JE. Molecular basis of pterygium development. *Semin Ophthalmol* 2016; 31(6): 567–583. <https://doi.org/10.3109/08820538.2014.971822>.
  5. Gumus K, Karakucuk S, Mirza GE, Akgun H, Arda H, Oner AO. Overexpression on vascular endothelial growth factor receptor 2 in pterygia may have a predictive value for a higher postoperative recurrence rate. *Br J Ophthalmol* 2014; 98(6): 796–800. <https://doi.org/10.1136/bjophthalmol-2012-301944>.
  6. Bianchi E, Scarinci F, Grande C, Plateroti R, Plateroti P, Plateroti AM, et al. Immunohistochemical profile VEGF, TGF- $\beta$  and PGE<sub>2</sub> in human pterygium and normal conjunctiva: experimental study and Review of the literature. *Int J Immunopathol Pharmacol* 2012 Jul-Sep; 25(3): 607–615. <https://doi.org/10.1177/039463201202500307>.
  7. Mohammed I. Treatment of pterygium. *Ann Afr Med* 2011; 10(3): 197–203. <http://www.annalsafmed.org/text.asp?2011/10/3/197/84695>.
  8. Zhou WP, Zhu YF, Zhang B, Qiu WY, Yao YF. The role of ultraviolet radiation in the pathogenesis of pterygia (Review). *Mol Med Rep* 2016 Jul; 14(1): 3–15. <https://pubmed.ncbi.nlm.nih.gov/27176595/>.
  9. Prabhasawat P, Tesavibul N, Leelapatranura K, Phonjan T. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. *Ophthalmology* 2006; 113(7): 1102–1109. <https://www.sciencedirect.com/science/article/abs/pii/S0161642006002867>.
  10. Murata M, Shimizu S, Horiuchi S, Taira M. Inhibitory effect of triamcinolone acetonide on corneal neovascularization. *Graefes's Arch Clin Exp Ophthalmol* 2006; 244(2): 205–209. <https://doi.org/10.1007/s00417-005-0036-1>.
  11. Gupta RK, Kumar S, Lakra MD. Intraoperative triamcinolone versus bevacizumab as an adjunct to conjunctival autograft in primary pterygium surgery. *IJMR* 2017; 4(2): 557–560. [https://www.ijcmr.com/uploads/7/7/4/6/77464738/ijcmr\\_1313\\_v1\\_mar\\_19.pdf](https://www.ijcmr.com/uploads/7/7/4/6/77464738/ijcmr_1313_v1_mar_19.pdf).
  12. Jim J, Guan M, Sima J, Gao G, Zhang M, Liu Z, et al. Decreased pigment epithelium derived factor and increased vascular endothelial growth factor levels in pterygia. *Cornea* 2003; 22(5): 473–477. <https://doi.org/10.1097/00003226-200307000-00015>.
  13. Fallah Tafti MR, Khosravifard K, Muhammadpour M, Hashemian MN, Kiarudi MY. Efficacy of intraslesional bevacizumab injection in decreasing pterygium size. *Cornea* 2011; 30(2): 127–129. <https://doi.org/10.1097/ICO.0b013e3181e16d67>.
  14. Bhargava P, Kochar A, Ali Khan N, Chandak A, Kumawat S, Garhwal J, et al. Comparison of pre-operative and post-operative astigmatism and visual acuity after pterygium excision followed by sutureless and gluefree conjunctival autograft. *Int J Biomed Res* 2015; 6(10): 800–804. <https://doi.org/10.7439/ijbr>.
  15. Hatta M, Surachmanto EE, Islam AA, Wahid S. Expression of mRNA IL-17F and sIL-17F in atopic asthma patients. *BMC Res Notes* 2017; 10: 202. <https://doi.org/10.1186/s13104-017-2517-9>.
  16. Syawal P, Budu B, Hatta M, Massi MN, Natzir R, Ichsan AM, et al. The effectiveness of triamcinolone injection on risk of postoperative operations with the conjunctiva autograft technique and its association with change of VEGF mRNA expression. *Biomed Pharmacol J* 2020; 13(2): 543–549. <https://doi.org/10.13005/bpj/1916>.
  17. Eko SE, Hatta M, Islam AA, Wahid S. Association between asthma control and Interleukin-17F expression level in adults patients with atopic asthma. *Saudi Med J* 2018; 39(7): 662–667. <https://doi.org/10.15537/smj.2018.7.22055>.
  18. Bahar I, Kaiserman I, McAllum P, Rootman D, Allan Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. *Curr Eye Res* 2008; 33(1): 23–28. <https://doi.org/10.1080/02713680701799101>.
  19. Razeghinejad MR, Hosseini H, Ahmadi F, Rahat F, Eghbal H. Preliminary results of subconjunctival bevacizumab in primary pterygium excision. *J Ophthalmic Vis Res* 2010; 43(3): 134–138. <https://doi.org/10.1159/000252980>.
  20. Kheirkah A, Nazari R, Safi H, Ghassemi H, Behrouz MJ, Raju VK. Effects of intraoperative steroid injection on the outcome of pterygium surgery. *Eye* 2013; 27(8): 906–914. <https://doi.org/10.1038/eye.2013.142>.
  21. Nava-Castañeda A, Ulloa-Orozco S, Garnica-Hayashi L, Hernandez-Orgaz J, Maria Carmen Jimenez-Martinez MC, Garfias Y, et al. Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium: one-year follow-up. *J Ocul Pharmacol Therapeut* 2015; 31(2): 106–113. [https://www.researchgate.net/publication/267813959\\_Triple\\_Subconjunctival\\_Bevacizumab\\_Injection\\_for\\_Early\\_Corneal\\_Recurrent\\_Pterygium\\_One-Year\\_Follow-Up/citation/download](https://www.researchgate.net/publication/267813959_Triple_Subconjunctival_Bevacizumab_Injection_for_Early_Corneal_Recurrent_Pterygium_One-Year_Follow-Up/citation/download).
  22. Nuzzi R, Tridico F. Efficacy of subconjunctival bevacizumab injections before and after surgical excision in preventing pterygium recurrence. *J Ophthalmol* 2017; 2017: 1–7. <https://doi.org/10.1155/2017/6824670>.
  23. Mpyet C, Oko H. Results of intra-operative 0.5mg/ml mitomycin C with 20mg depo steroid in the treatment of primary pterygium. *Cent Afr J Med* 2000; 46(12): 330–332. <https://doi.org/10.4314/cajm.v46i12.8580>.
  24. Voronov E, Carmi Y, Apte RN. The role IL-1 in tumor-mediated angiogenesis. *Front Physiol* 2014; 5: 114. <https://doi.org/10.3389/fphys.2014.00114>.
  25. Karazeli A, Kucurkerdonmez C, Akova YA, Koktekir BE. Does Topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting? *Int J Ophthalmol* 2014; 7(3): 512–516. <https://doi.org/10.3980/j.issn.2222-3959.2014.03.23>.
  26. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch Y, Dinarello CA, et al. IL-1 is required for tumor invasiveness and angiogenesis. *Proc Natl Acad Sci Unit States Am* 2003; 100(5): 2645–2650. <https://doi.org/10.1073/pnas.0437939100>.
  27. Honnegowda TM, Kumar P, Udupa EG, Kumar S, Kumar U, Rao P, et al. Role of angiogenesis and angiogenic factors in acute and chronic wound healing. *Plast Aesthet Res* 2015; 2: 243–249. <https://doi.org/10.4103/2347-9264.165438>.
  28. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; 144(5): 646–674. <https://doi.org/10.1016/j.cell.2011.02.013>.
  29. Kang S, Chung SK. The effect of subconjunctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits. *Cornea* 2010; 29(2): 192–196. <https://doi.org/10.1097/ico.0b013e3181b1c82f>.

**How to cite this article:** Syawal P, Budu B, Hatta M, Massi MN, Ichsan AM, Minhajat R. Comparison between the triamcinolone and bevacizumab subconjunctivals and changes in Interleukin-1 mRNA expression in pterygium. *J Taibah Univ Med Sc* 2022;17(1):67–71.